美国幽门螺杆菌感染一线方案的成本效果分析
该研究采用马尔可夫模型,从美国医疗支付方角度评估5种幽门螺杆菌根除方案在1年、10年、20年及终身时间范围内的成本效果。结果显示铋剂四联疗法终身成本最低(每例193,651美元),为成本效果最优的一线方案;利福布汀三联疗法为成本效果可接受的替代方案。
要点
- 铋剂四联疗法终身成本最低,为每例193,651美元,是成本效果最优的一线方案。
- 利福布汀三联疗法增量成本效果比为每获得1个质量调整生命年45,971美元,为可接受的替代方案。
- 克拉霉素三联疗法和伏诺拉生双联疗法被铋剂四联疗法主导。
核心结论
- 铋剂四联疗法是美国治疗初治幽门螺杆菌感染具有成本效果的一线方案,利福布汀三联疗法为成本效果可接受的替代方案。
研究设计与样本
- 采用马尔可夫模型,从美国医疗支付方角度评估5种幽门螺杆菌根除方案。
- 模拟初治成人幽门螺杆菌感染假设队列,时间范围包括1年、10年、20年及终身。
- 5种方案为:克拉霉素三联疗法、伏诺拉生双联疗法、伏诺拉生三联疗法、利福布汀三联疗法和铋剂四联疗法。
- 结局指标为增量成本效果比和净货币收益,支付意愿阈值为每质量调整生命年100,000美元和150,000美元。
主要发现
- 铋剂四联疗法终身每例成本最低,为193,651美元,作为参照方案。
- 利福布汀三联疗法增量成本效果比为每质量调整生命年45,971美元。
- 伏诺拉生三联疗法增量成本效果比为每质量调整生命年290,572美元。
- 克拉霉素三联疗法和伏诺拉生双联疗法被铋剂四联疗法主导。
- 利福布汀三联疗法净货币收益最高,其次为铋剂四联疗法;在10年和20年时间范围情景分析中仍保持最高净货币收益。
关键数值与推荐
- 利福布汀三联疗法增量成本效果比为每质量调整生命年45,971美元。
- 伏诺拉生三联疗法增量成本效果比为每质量调整生命年290,572美元。
- 铋剂四联疗法终身每例成本为193,651美元。
- 敏感性分析显示铋剂四联疗法的根除率是最具影响的参数之一。
- 概率敏感性分析显示利福布汀三联疗法在两个支付意愿阈值下具有最高成本效果概率,其次为铋剂四联疗法。
临床怎么用
- 政策制定者应优先考虑铋剂四联疗法和利福布汀三联疗法,而非其他方案。
- 临床决策可参考本研究将铋剂四联疗法作为初治患者的一线选择。
- 利福布汀三联疗法可作为铋剂四联疗法的成本效果可接受替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Helicobacter pylori infection remains a significant global health burden. The 2024 American College of Gastroenterology guideline recommended bismuth quadruple therapy (BQT) as the first-line treatment for treatment-naive patients. This study aimed to assess the cost-effectiveness of 5 regimens from a US healthcare payer perspective. METHODS: A Markov model was used to evaluate 5 H. pylori eradication regimens: (i) clarithromycin triple therapy, (ii) vonoprazan dual therapy, (iii) vonoprazan triple therapy, (iv) rifabutin triple therapy, and (v) BQT. We simulated a hypothetical cohort of treatment-naïve adults with H. pylori over 1-, 10-, 20-year and lifetime horizons. Model outcomes were measured in incremental cost-effectiveness ratios and net monetary benefit (NMB) at willingness-to-pay thresholds of $100,000 and $150,000/quality-adjusted life year. Deterministic and probabilistic sensitivity analysis was performed to assess model robustness. RESULTS: BQT had the lowest lifetime cost per patient ($193,651) and was used as the reference. Rifabutin and vonoprazan triple therapies had incremental cost-effectiveness ratios of $45,971 and $290,572 per quality-adjusted life year gained, respectively. Clarithromycin triple and vonoprazan dual therapies were dominated by BQT. Rifabutin triple therapy had the highest NMB, followed by BQT. Scenario analysis confirmed that rifabutin triple therapy maintained the highest NMB over 10- and 20-year horizons. Sensitivity analyses identified eradication rates of BQT were among the most influential parameters. Probabilistic sensitivity analysis showed rifabutin triple therapy had the highest probability of being cost-effective at both willingness-to-pay thresholds, followed by BQT. DISCUSSION: BQT was found to be the cost-effective first-line treatment. Rifabutin triple therapy was a cost-effective alternative. Policymakers should prioritize BQT and rifabutin triple therapy versus other therapies.
引用
- Liu L, Wang K, Neidecker MV, et al. Cost-Effectiveness of First-Line Regimens for Helicobacter pylori Infection in the United States. Am J Gastroenterol. 2026. PMID: 41563134. doi:10.14309/ajg.0000000000003924
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。